Tamas Revesz

List of Publications by Year in descending order

189 papers	24,573 citations	8181 76 h-index	7745 150 g-index
208 all docs	208 docs citations	208 times ranked	20830 citing authors

#	Article	IF	Citations
1	Dissecting the Phenotype and Genotype of <scp>PLA2G6</scp>â€Related Parkinsonism. Movement Disorders, 2022, 37, 148-161.	3.9	32
2	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	7.6	9
3	Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature, 2022, 605, 310-314.	27.8	88
4	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	3.9	3
5	Neuropathological and Biomarker Findings in Parkinsonâ€™s Disease and Alzheimerâ€™s Disease: From Protein Aggregates to Synaptic Dysfunction. Journal of Parkinson's Disease, 2021, 11, 107-121.	2.8	28
6	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
7	Structure-based classification of tauopathies. Nature, 2021, 598, 359-363.	27.8	409
8	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan. Neurobiology of Disease, 2021, 158, 105452.	4.4	5
9	MOBP and HIP1 in multiple system atrophy: New Î±â€synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis. Neuropathology and Applied Neurobiology, 2021, 47, 640-652.	3.2	11
10	White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy. Acta Neuropathologica, 2020, 139, 135-156.	7.7	42
11	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
12	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
13	Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R. Neurobiology of Disease, 2020, 146, 105079.	4.4	4
14	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
15	Tau Isoform-Driven CBD Pathology Transmission in Oligodendrocytes in Humanized Tau Mice. Frontiers in Neurology, 2020, 11, 589471.	2.4	5
16	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
17	LATE to the PART-y. Brain, 2019, 142, e47-e47.	7.6	44
18	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16

#	Article	IF	Citations
19	A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders. Journal of Physical Education and Sports Management, 2019, 5, a003913.	1.2	19
20	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
21	Primum non nocere: a call for balance when reporting on CTE. Lancet Neurology, The, 2019, 18, 231-233.	10.2	48
22	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
23	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
24	The aftermath of boxing revisited: identifying chronic traumatic encephalopathy pathology in the original Corsellis boxer series. Acta Neuropathologica, 2018, 136, 973-974.	7.7	28
25	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
26	The presubiculum is preserved from neurodegenerative changes in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 62.	5.2	9
27	Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. Neurocase, 2018, 24, 166-174.	0.6	40
28	The clinical, neuroanatomical, and neuropathologic phenotype of TBK1â€associated frontotemporal dementia: A longitudinal case report. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 75-81.	2.4	28
29	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathologica, 2017, 133, 337-352.	7.7	193
30	Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain, 2017, 140, 2820-2837.	7.6	64
31	[P2â€“441]: PATHOLOGICAL CORRELATES OF WHITE MATTER HYPERINTENSITIES ON CADAVERIC MRI IN PROGRANULINâ€ASSOCIATED FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P805.	0.8	0
32	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	9.0	162
33	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
34	[P2â€“158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION. Alzheimer's and Dementia, 2017, 13, P668.	0.8	0
35	1115â€…Chronic traumatic encephalopathy in retired footballers with dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A1.1-A1.	1.9	0
36	Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathologica, 2016, 132, 531-543.	7.7	173

#	Article	IF	Citations
37	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
38	The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions. Neurobiology of Aging, 2016, 46, 192-203.	3.1	20
39	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	7.6	107
40	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimerâ€™s disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
41	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. Movement Disorders, 2016, 31, 668-675.	3.9	31
42	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78
43	Characterization of tau positron emission tomography tracer [¹⁸F]AVâ€1451 binding to postmortem tissue in Alzheimer's disease,Âprimary tauopathies, and other dementias. Alzheimer's and Dementia, 2016, 12, 1116-1124.	0.8	161
44	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	6.2	333
45	Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 633-641.	1.9	11
46	Review: An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathology and Applied Neurobiology, 2015, 41, 858-881.	3.2	168
47	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
48	Serotonergic markers in Parkinson's disease and levodopaâ€induced dyskinesias. Movement Disorders, 2015, 30, 796-804.	3.9	32
49	Minimal change multiple system atrophy: An aggressive variant?. Movement Disorders, 2015, 30, 960-967.	3.9	45
50	Temporal Variant Frontotemporal Dementia Is Associated with Globular Glial Tauopathy. Cognitive and Behavioral Neurology, 2015, 28, 92-97.	0.9	20
51	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
52	Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiology of Aging, 2015, 36, 546.e1-546.e7.	3.1	48
53	The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. Neurobiology of Aging, 2015, 36, 1221.e1-1221.e6.	3.1	39
54	Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1069-1074.	2.6	22

#	Article	IF	Citations
55	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 291-301.	10.2	270
56	Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. Neurobiology of Aging, 2015, 36, 1223.e1-1223.e2.	3.1	25
57	Brain Amyloid-Beta Fragment Signatures in Pathological Ageing and Alzheimer's Disease by Hybrid Immunoprecipitation Mass Spectrometry. Neurodegenerative Diseases, 2015, 15, 50-57.	1.4	41
58	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
59	Alterations in global <scp>DNA</scp> methylation and hydroxymethylation are not detected in <scp>A</scp>lzheimer's disease. Neuropathology and Applied Neurobiology, 2015, 41, 497-506.	3.2	78
60	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
61	Histological evidence of chronic traumatic encephalopathy in a large series of neurodegenerative diseases. Acta Neuropathologica, 2015, 130, 891-893.	7.7	92
62	A 30-unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP-43 inclusions and clinical disease. Acta Neuropathologica, 2015, 130, 599-601.	7.7	31
63	Neuropathy target esterase impairments cause Oliverâ€“McFarlane and Laurenceâ€“Moon syndromes. Journal of Medical Genetics, 2015, 52, 85-94.	3.2	91
64	Evaluating the relationship between amyloid-Î² and Î±-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinsonâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 77.	6.2	74
65	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
66	<scp>TDP</scp>â€43 pathology is present in most postâ€encephalitic parkinsonism brains. Neuropathology and Applied Neurobiology, 2014, 40, 654-657.	3.2	9
67	Alphaâ€synuclein mRNA expression in oligodendrocytes in MSA. Glia, 2014, 62, 964-970.	4.9	149
68	A pathogenic progranulin mutation and <scp>C9orf72</scp> repeat expansion in a family with frontotemporal dementia. Neuropathology and Applied Neurobiology, 2014, 40, 502-513.	3.2	37
69	A 6.4 Mb Duplication of the Î±-Synuclein Locus Causing Frontotemporal Dementia and Parkinsonism. JAMA Neurology, 2014, 71, 1162.	9.0	60
70	Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. Acta Neuropathologica Communications, 2014, 2, 24.	5.2	21
71	The Significance of Î±-Synuclein, Amyloid-Î² and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. Neurodegenerative Diseases, 2014, 13, 154-156.	1.4	83
72	MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy. Journal of Neurology, 2013, 260, 1031-1036.	3.6	22

#	Article	IF	Citations
73	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathologica, 2013, 126, 401-409.	7.7	126
74	A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy. New England Journal of Medicine, 2013, 369, 1904-1914.	27.0	113
75	Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica, 2013, 126, 537-544.	7.7	168
76	Neuropathological findings in benign tremulous Parkinsonism. Movement Disorders, 2013, 28, 145-152.	3.9	68
77	The midbrain to pons ratio. Neurology, 2013, 80, 1856-1861.	1.1	153
78	TDP-43 pathology in a patient carrying G2019S LRRK2Âmutation and a novel p.Q124E MAPT. Neurobiology of Aging, 2013, 34, 2889.e5-2889.e9.	3.1	41
79	Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias. Neurobiology of Aging, 2013, 34, 1416-1425.	3.1	14
80	Parkin Disease. JAMA Neurology, 2013, 70, 571.	9.0	119
81	The more cortical amyloidâ€Î², the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?. Movement Disorders, 2013, 28, 263-264.	3.9	2
82	Î±-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinsonâ€™s disease and multiple system atrophy?. Acta Neuropathologica, 2013, 125, 753-769.	7.7	369
83	Genetic Analysis of Inherited Leukodystrophies. JAMA Neurology, 2013, 70, 875.	9.0	147
84	Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1411-1412.	1.9	9
85	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
86	C9ORF72 expansions, parkinsonism, and Parkinson disease. Neurology, 2013, 81, 808-811.	1.1	57
87	A NOVEL TAUOPATHY PRESENTING WITH A MOTOR NEURONE DISEASE PHENOTYPE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.123-e2.	1.9	0
88	Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and <scp>P</scp>arkinson's Disease. Brain Pathology, 2013, 23, 263-273.	4.1	69
89	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2013, 28, 408-408.	3.9	0
90	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain, 2012, 135, 736-750.	7.6	392

#	Article	IF	Citations
91	Difference in MSA Phenotype Distribution between Populations: Genetics or Environment?. Journal of Parkinson's Disease, 2012, 2, 7-18.	2.8	33
92	Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiology of Aging, 2012, 33, 814-823.	3.1	184
93	Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiology of Aging, 2012, 33, 426.e13-426.e21.	3.1	67
94	Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiology of Aging, 2012, 33, 838.e7-838.e11.	3.1	23
95	The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiology of Aging, 2012, 33, 2231.e7-2231.e14.	3.1	60
96	The Spread of Neurodegenerative Disease. New England Journal of Medicine, 2012, 366, 2126-2128.	27.0	80
97	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2012, 27, 1754-1762.	3.9	163
98	Multiple system atrophyâ€“parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2012, 27, 1186-1190.	3.9	164
99	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	21.4	502
100	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Molecular Genetics and Metabolism, 2011, 103, 410-412.	1.1	40
101	Mutational analysis of parkin and PINK1 in multiple system atrophy. Neurobiology of Aging, 2011, 32, 548.e5-548.e7.	3.1	16
102	Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 277-286.	2.8	106
103	TDP-43 pathology may occur in the BRI2 gene-related dementias. Acta Neuropathologica, 2011, 121, 559-560.	7.7	3
104	Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica, 2011, 122, 187-204.	7.7	357
105	Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathologica, 2011, 122, 415-428.	7.7	67
106	Transportin1: a marker of FTLD-FUS. Acta Neuropathologica, 2011, 122, 591-600.	7.7	58
107	Postural instability, frontotemporal dementia, and ophthalmoplegia: Clinicopathological case. Movement Disorders, 2011, 26, 1808-1813.	3.9	2
108	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain, 2011, 134, 2548-2564.	7.6	76

#	Article	IF	Citations
109	Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain, 2011, 134, 2565-2581.	7.6	306
110	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain, 2011, 134, 1493-1505.	7.6	497
111	The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1405-1407.	1.9	32
112	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	7.6	132
113	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
114	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	7.7	222
115	Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathologica, 2010, 120, 327-341.	7.7	64
116	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	3.9	43
117	Impulsiveâ€compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Movement Disorders, 2010, 25, 638-642.	3.9	33
118	Genetic variability at the PARK16 locus. European Journal of Human Genetics, 2010, 18, 1356-1359.	2.8	85
119	Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain, 2010, 133, 1755-1762.	7.6	349
120	Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain, 2010, 133, 2045-2057.	7.6	414
121	Lesions Associated with Cognitive Impairment and Dementia. , 2010, , 261-287.		1
122	CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE. Hirosaki Medical Journal, 2010, 61, S111-S124.	1.0	16
123	PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM. Hirosaki Medical Journal, 2010, 61, S262-S269.	1.0	1
124	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 2009, 132, 1783-1794.	7.6	612
125	SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 2009, 65, 610-614.	5.3	257
126	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	7.7	377

#	Article	IF	Citations
127	Can olfactory bulb biopsy be justified for the diagnosis of Parkinsonâ€™s disease? Comments on â€œolfactory bulb Î±-synucleinopathy has high specificity and sensitivity for Lewy body disordersâ€. Acta Neuropathologica, 2009, 117, 213-214.	7.7	23
128	Assessment of Î²-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
129	Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica, 2009, 118, 115-130.	7.7	255
130	The genetics of Parkinson's syndromes: a critical review. Current Opinion in Genetics and Development, 2009, 19, 254-265.	3.3	195
131	Clinical and pathological features of an Alzheimer's disease patient with the MAPT Î”K280 mutation. Neurobiology of Aging, 2009, 30, 388-393.	3.1	55
132	Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neuroscience Letters, 2009, 453, 77-80.	2.1	110
133	Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate?. Neuroscience Letters, 2009, 467, 208-211.	2.1	19
134	Parkinson's disease. Lancet, The, 2009, 373, 2055-2066.	13.7	1,835
135	MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathologica, 2008, 116, 103-118.	7.7	52
136	Cortical Î±-synuclein load is associated with amyloid-Î² plaque burden in a subset of Parkinsonâ€™s disease patients. Acta Neuropathologica, 2008, 115, 417-425.	7.7	146
137	LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathologica, 2008, 116, 639-646.	7.7	43
138	Research in motion: the enigma of Parkinson's disease pathology spread. Nature Reviews Neuroscience, 2008, 9, 741-745.	10.2	296
139	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 2008, 14, 501-503.	30.7	1,595
140	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain, 2008, 131, 706-720.	7.6	222
141	Parietal Lobe Deficits in Frontotemporal Lobar Degeneration Caused by a Mutation in the Progranulin Gene. Archives of Neurology, 2008, 65, 506.	4.5	52
142	Diseases of movement and system degenerations. , 2008, , 889-1030.		8
143	Adult-Onset Neurodegeneration With Brain Iron Accumulation and Cortical Î±-Synuclein and Tau Pathology. Archives of Neurology, 2007, 64, 280.	4.5	35
144	Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain, 2007, 130, 1566-1576.	7.6	364

#	Article	IF	Citations
145	Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: Similarities with Alzheimer's disease. Journal of the Neurological Sciences, 2007, 257, 88-96.	0.6	24
146	Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Movement Disorders, 2007, 22, 895-897.	3.9	25
147	Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy. Movement Disorders, 2007, 22, 2235-2241.	3.9	216
148	Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nature Genetics, 2007, 39, 1434-1436.	21.4	185
149	The phagocytic capacity of neurones. European Journal of Neuroscience, 2007, 25, 2947-2955.	2.6	41
150	DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. Neurobiology of Disease, 2007, 28, 122-132.	4.4	32
151	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathologica, 2006, 111, 329-340.	7.7	91
152	NR4A2 genetic variation in sporadic Parkinson's disease: A genewide approach. Movement Disorders, 2006, 21, 1960-1963.	3.9	15
153	UCHL-1is not a Parkinson's disease susceptibility gene. Annals of Neurology, 2006, 59, 627-633.	5.3	123
154	UCHL-1 gene in multiple system atrophy: A haplotype tagging approach. Movement Disorders, 2005, 20, 1338-1343.	3.9	17
155	Sporadic four-repeat tauopathy with frontotemporal degeneration, parkinsonism and motor neuron disease. Acta Neuropathologica, 2005, 110, 600-609.	7.7	30
156	Familial Danish Dementia. Journal of Biological Chemistry, 2005, 280, 36883-36894.	3.4	59
157	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128, 2786-2796.	7.6	315
158	A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet, The, 2005, 365, 415-416.	13.7	391
159	Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain, 2005, 128, 1247-1258.	7.6	743
160	The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain, 2004, 127, 420-430.	7.6	404
161	The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain, 2004, 127, 2657-2671.	7.6	493
162	Detecting tau isoforms in archival cases. Acta Neuropathologica, 2004, 107, 181-182.	7.7	3

#	Article	IF	Citations
163	Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Movement Disorders, 2004, 19, 630-640.	3.9	332
164	Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Human Molecular Genetics, 2004, 13, 1219-1224.	2.9	93
165	Familial and sporadic cerebral amyloid angiopathies associated with dementia and the BRI dementias. , 2004, , 330-352.		8
166	Anatamopathological spectrum of tauopathies. Movement Disorders, 2003, 18, 13-20.	3.9	20
167	Cerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View. Journal of Neuropathology and Experimental Neurology, 2003, 62, 885-898.	1.7	245
168	Neurofilament inclusion body disease: a new proteinopathy?. Brain, 2003, 126, 2291-2303.	7.6	176
169	Complement Activation in Chromosome 13 Dementias. Journal of Biological Chemistry, 2002, 277, 49782-49790.	3.4	59
170	Familial Danish Dementia: A Novel Form of Cerebral Amyloidosis Associated with Deposition of Both Amyloid-Dan and Amyloid-Beta. Journal of Neuropathology and Experimental Neurology, 2002, 61, 254-267.	1.7	116
171	Sporadic and Familial Cerebral Amyloid Angiopathies. Brain Pathology, 2002, 12, 343-357.	4.1	172
172	Regional Distribution of Amyloid-Bri Deposition and Its Association with Neurofibrillary Degeneration in Familial British Dementia. American Journal of Pathology, 2001, 158, 515-526.	3.8	127
173	Sequence, genomic structure and tissue expression of Human BRI 3 , a member of the BRI gene family. Gene, 2001, 266, 95-102.	2.2	50
174	A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies. Neuroscience Letters, 2001, 313, 93-95.	2.1	54
175	Chromosome 13 dementia syndromes as models of neurodegeneration. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 277-284.	3.0	29
176	A multidisciplinary team approach to skull base chondrosarcomas. Journal of Neurosurgery, 2001, 95, 184-189.	1.6	100
177	Systemic Amyloid Deposits in Familial British Dementia. Journal of Biological Chemistry, 2001, 276, 43909-43914.	3.4	73
178	A Pathogenic Presenilin-1 Deletion Causes Abberrant AÎ²42 Production in the Absence of Congophilic Amyloid Plaques. Journal of Biological Chemistry, 2001, 276, 7233-7239.	3.4	76
179	A multidisciplinary team approach to skull base chordomas. Journal of Neurosurgery, 2001, 95, 175-183.	1.6	151
180	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-? concentrations. Annals of Neurology, 2000, 48, 806-808.	5.3	135

#	Article	IF	Citations
181	Familial British dementia with amyloid angiopathy. Brain, 2000, 123, 975-991.	7.6	104
182	Axonal lesions in multiple sclerosis: an old story revisited. Brain, 2000, 123, 203-204.	7.6	7
183	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PSâ€1 mutations that lead to exceptionally high amyloidâ€î² concentrations. Annals of Neurology, 2000, 48, 806-808.	5.3	3
184	A stop-codon mutation in the BRI gene associated with familial British dementia. Nature, 1999, 399, 776-781.	27.8	467
185	A Case of Sporadic Pick Disease With Onset at 27 Years. Archives of Neurology, 1999, 56, 1289.	4.5	14
186	Central benzodiazepine receptor autoradiography in hippocampal sclerosis. British Journal of Pharmacology, 1997, 122, 358-364.	5.4	55
187	Skull base chordomas: A review of 38 patients, 1958â€“88. British Journal of Neurosurgery, 1993, 7, 241-248.	0.8	102
188	Familial British Dementia. , 0, , 487-493.		0
189	A Decamer Duplication in the BRI Gene Originates a de novo Amyloid Peptide that Causes Dementia in a Danish Kindred. , 0, , 507-513.		0